CD27 and pancreatic neoplasm: For tumors which are immunologically “cold” (123) due to a low tumor mutational burden such as pancreatic cancer, CD27 agonistic mAbs in combination with tumor-antigen loaded DC could be used to expand the T cell repertoire.